National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical Trial Optional)
ID: 340133Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/340133

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-143.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical Trial Optional)." This initiative aims to advance the discovery and preclinical development of innovative therapies for mental disorders and alcohol use disorder (AUD), encouraging collaborative proposals from academia, biotechnology, and industry to develop pharmacologic and neuromodulatory tools. The program emphasizes the importance of multidisciplinary collaborations to address critical health needs, with a focus on novel therapeutics, biomarker validation, and early-stage human studies to assess safety and efficacy. Interested applicants must adhere to strict application guidelines and deadlines, with the submission deadline set for February 24, 2025. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional information can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-143.html.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-143.html
    The National Cooperative Drug/Device Discovery/Development Groups (NCDDG) funding opportunity, led by the National Institutes of Health (NIH), aims to enhance the translation of innovative therapies for mental disorders and alcohol use disorder (AUD) from discovery to early human trials. The initiative encourages collaborative proposals from academia, biotechnology, and industry, focusing on the development of pharmacologic and neuromodulatory tools. Key objectives include the discovery of novel therapeutics, validation of biomarkers, and early-stage human studies to assess safety and efficacy. The funding is available through U01 cooperative agreements, and applicants must adhere to strict application guidelines and deadlines, including data management and sharing plans. The NCDDG program fosters multidisciplinary collaborations to advance research, thereby addressing critical health needs while adhering to NIH policies on human subject protection and data sharing. Ultimately, this initiative seeks to leverage combined resources to facilitate effective treatments for psychiatric and addictive disorders while ensuring robust scientific rigor and regulatory compliance in research practices.
    Similar Opportunities
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)." This initiative aims to advance the discovery and development of innovative drug and device therapies targeting mental disorders and alcohol use disorder (AUD) through collaborative efforts among academia, biotechnology, and pharmaceutical sectors. The program emphasizes multidisciplinary approaches and partnerships to facilitate early-phase human trials, develop pharmacologic and neuromodulatory tools, and validate experimental therapeutic studies. Eligible applicants include a wide range of organizations, such as educational institutions and nonprofits, with no cap on application budgets, although realistic estimates are expected. The total project period cannot exceed five years, and applications must adhere to NIH guidelines. Interested parties can find more information and submit inquiries via email to OERWebmaster03@od.nih.gov, with the application deadline set for February 24, 2025.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) aimed at promoting research for innovative behavioral and integrative treatments for drug and alcohol use disorders. This initiative encourages the development and testing of interventions across various stages, from initial generation and refinement to efficacy testing in controlled and real-world settings, focusing on enhancing treatment efficacy and accessibility, particularly in community environments. Applications are welcomed from a diverse range of organizations, including higher education institutions and for-profit entities, with no budget limit specified, and must be submitted by March 21, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-182.html.
    Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)" aimed at advancing research in the treatment and recovery from alcohol use disorder (AUD). This grant supports clinical trials focusing on various aspects of AUD, including medication development, behavioral therapies, and innovative treatment technologies, particularly for populations facing health disparities. The funding is crucial for enhancing the understanding and efficacy of AUD treatments, ultimately contributing to improved public health outcomes. Eligible applicants can receive up to $500,000 in direct costs over a maximum project period of five years, with key submission deadlines on October 5, 2023, and February 5, 2024. For more information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-250.html.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)" aimed at advancing the development of Digital Therapeutics (DTx) for treating Substance Use Disorders (SUDs). This initiative seeks to support the creation of safe and effective clinical-grade digital platforms that can deliver therapeutic treatments, particularly for conditions that currently lack FDA-approved medications. The funding mechanism involves a two-phase cooperative agreement, with the UG3 phase focusing on initial milestones and design testing for up to two years, followed by the UH3 phase, which can extend for an additional three years upon successful completion of the UG3 phase. Eligible applicants include a diverse range of organizations, such as educational institutions, tribal governments, and community-based organizations. The application process opens on February 26, 2024, with multiple deadlines extending through late 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Funding Opportunity Announcement (FOA) aimed at supporting the development of medications for Alcohol Use Disorder (AUD) and Alcohol-Associated Organ Damage (AAOD) through Small Business Innovation Research (SBIR) applications. Eligible applicants, specifically U.S.-based small businesses, are required to propose therapeutic agents that have a solid foundation of background data, ready for transition to preclinical and clinical development, with a focus on advancing these candidates towards FDA approval. This initiative is critical given the limited FDA-approved treatments available for AUD and AAOD, and it emphasizes the importance of rigorous scientific and regulatory standards in drug development. Funding amounts include up to $1 million for Phase I and $1.5 million for Phase II, with project durations of up to two years and three years, respectively. Interested parties can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with the application deadline set for December 4, 2024.
    Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)" aimed at accelerating the development of innovative devices to treat Substance Use Disorders (SUDs). The initiative seeks proposals that focus on advancing neuromodulatory or neurophysiological devices through various stages of the FDA approval process, with an emphasis on understanding treatment mechanisms and their efficacy. Eligible applicants include a diverse range of organizations, such as academic institutions, nonprofits, and tribal governments, with a maximum budget of $500,000 per year for the UG3 phase, which lasts up to two years before transitioning to the UH3 phase for an additional three years. Applications will open on November 18, 2023, with awards expected to commence by December 2023; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for first-in-human and early-stage clinical trials of novel investigational drugs or devices aimed at treating psychiatric disorders, under the U01 Clinical Trial Required mechanism. This initiative seeks to support innovative clinical trials that address significant unmet medical needs in psychiatric care, emphasizing the formation of partnerships between biomedical researchers and industry to expedite the development of effective therapies. The total funding available for this program is $27 million, with project durations ranging from 1 year for first-in-human studies to up to 4 years for comprehensive Phase II studies. Interested applicants, including higher education institutions, nonprofits, and governmental entities, must adhere to strict application guidelines, with a submission deadline of October 15, 2024. For further information, applicants can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement page at http://grants.nih.gov/grants/guide/pa-files/PAR-21-133.html.
    Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant aimed at advancing drug discovery for nervous system disorders. This initiative focuses on the identification, design, synthesis, and preclinical testing of novel therapeutic compounds, particularly emphasizing innovative approaches to drug metabolism and pharmacokinetics, while excluding clinical trial applications. The program encourages high-risk, novel projects that aim to translate scientific research into effective treatments for conditions such as mental illness and substance use disorders. Interested applicants can find more information and guidelines in the NIH Grant Application Guide, with applications due by January 7, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.